Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Consistent long-term performance driving confidence for the future - Consistent strong performance since 2018. Confident in our sales growth outlook CAGR 4% to 2025 Sales USD bn, % CAGR CC Core Oplnc USD bn, % CAGR CC Innovative Medicines Core margin (%), growth bps cc +6% 38.4 35.0 35.9 33.3 +13% 12.8 11.9 10.6 9.4 32.4 +220bps 34.3 +90bps +270bps 37.1 36.3 9M 2018 9M 2019 9M 2020 9M 2021 9M 2018 9M 2019 9M 2020 9M 2021 9M 2018 9M 2019 9M 2020 9M 2021 All growth % in cc IM - Innovative Medicines division Constant currencies (cc), core results are non-IFRS measures; explanation can be found on page 47 of Condensed Interim Financial Report. Unless otherwise noted, all growth rates refer to same period in PY 5 Investor Relations | Q3 2021 Results ✓ NOVARTIS | Reimagining Medicine

View entire presentation